This strategy was tested in a recent study where the selective pressure exerted by EGFR inhibitors in lung cancer was shown to induce APOBEC3B overexpression, leading to increased cancer cell mutability, fostering tumour adaptation to treatment (preprint: Mayekar et al, 2020). The gene discussed is EGFR; the disease is cancer.